Get the Stockscreener App
7.77
4.78%
-0.39
After Hours:
7.77
Cullinan Therapeutics Inc stock is traded at $7.77, with a volume of 241.75K.
It is down -4.78% in the last 24 hours and up +3.19% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.16
Open:
$8.05
24h Volume:
241.75K
Relative Volume:
0.65
Market Cap:
$458.54M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.1057
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-6.72%
1M Performance:
+3.19%
6M Performance:
-26.42%
1Y Performance:
-59.84%
1-Day Range:
$7.75
$8.15
1-Week Range:
$7.75
$8.59
52-Week Range:
$6.85
$19.89
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.77 | 481.56M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Real time social sentiment graph for Cullinan Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer - Insider Monkey
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionAI Screener for Daily Stock Forecast - Newser
How to integrate Cullinan Therapeutics Inc. into portfolio analysis toolsIntelligent Trade Forecast With AI Analytics - Newser
What is Cullinan Therapeutics Inc. company’s growth strategyFinancial News Trend Scanner For Every Investor - jammulinksnews.com
Market reaction to Cullinan Therapeutics Inc.’s recent newsReal-Time Setup Summary with ROI Focus - Newser
How Cullinan Therapeutics Inc. stock performs during market volatilityFree Daily Profit Focused Stock Screener - Newser
Does Cullinan Therapeutics Inc. fit your quant trading modelFree Triple Return Setup with Risk Control - Newser
Using data models to predict Cullinan Therapeutics Inc. stock movementBreakout Watcher with Entry and Exit Alerts - Newser
What to expect from Cullinan Therapeutics Inc. in the next 30 daysSmart Money Strategy for Growth Stocks - Newser
Has Cullinan Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Real Time Trade Opportunity Alerts - Newser
Analyzing net buyer seller activity in Cullinan Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Why is Cullinan Therapeutics Inc. stock attracting strong analyst attentionFree Investment Timing Strategies - jammulinksnews.com
Published on: 2025-07-29 02:53:41 - metal.it
What are Cullinan Therapeutics Inc. company’s key revenue driversDaily Trading Signals That Work - jammulinksnews.com
How volatile is Cullinan Therapeutics Inc. stock compared to the marketFinancial News Report That Work - jammulinksnews.com
What are the latest earnings results for Cullinan Therapeutics Inc.Turbocharged investment results - jammulinksnews.com
What makes Cullinan Therapeutics Inc. stock price move sharplyMarket-leading growth rates - jammulinksnews.com
When is Cullinan Therapeutics Inc. stock expected to show significant growthAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Is Cullinan Therapeutics Inc. stock overvalued or undervaluedUnlock steady growth with low-risk stocks - jammulinksnews.com
Does Cullinan Therapeutics Inc. fit your quant trading model Swing Trade Watchlist with Entry Zones - Newser
What is the dividend policy of Cullinan Therapeutics Inc. stockStrong return on assets - jammulinksnews.com
What are analysts’ price targets for Cullinan Therapeutics Inc. in the next 12 monthsMaximize portfolio growth with expert advice - jammulinksnews.com
How many analysts rate Cullinan Therapeutics Inc. as a “Buy”Unlock daily market insights for better trades - jammulinksnews.com
How Efficient Is Cullinan Therapeutics Inc. at Controlling Operating CostsWeekly Growth Portfolio Performance Summary - Newser
What analysts say about Cullinan Therapeutics Inc. stockBreakneck growth rates - PrintWeekIndia
When is the best time to buy Cullinan Therapeutics Inc. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives Cullinan Therapeutics Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Cullinan Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - The Malaysian Reserve
Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):